Recombinant Human CD93 protein (mFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

mFc Tag

Activity

not tested

Cat no : Eg3881

---

Validation Data Gallery

• 

  Purity of Recombinant Human CD93 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human CD93 protein Ala24-Lys580 (Accession# Q9NPY3) with a mouse IgG Fc tag at the C-terminus.
• GeneID: 22918
• Accession: Q9NPY3
• PredictedSize: 84.7 kDa
• SDS-PAGE: 100-130 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD93 (also known as complement protein 1 q subcomponent receptor C1qR1 or C1qRp), is a transmembrane glycoprotein, that belongs to the C-type lectin domain (CTLD) group 14 family of transmembrane glycoproteins together with thrombomodulin, CLEC14A, and CD248. This protein family has a similar ectodomain architecture and is involved in several cell processes including angiogenesis, inflammation, and cell adhesion. CD93 is predominantly co-expressed on tumor and stromal cells, such as endothelial cells, cancer-associated fibroblasts(CAFs), neutrophils, T cells, macrophages, M1 and M2 macrophages. Several immune-related signaling pathways were enriched based on CD93 expression, including immune cell activation and migration, focal adhesion, leukocyte transendothelial migration, oxidative phosphorylation, and complement.

References:

1. Giovanni Tossetta. et al. (2023). Cells. 12(13):1778.
2. Kabir A Khan. et al. (2019). FEBS J. 286(17):3299-3332.
3. Aiyuan Guo. et al. (2022). Front Immunol. 13:907182.